The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Increased NADP reduced (NADPH) oxidase 4 (Nox4) and reduced expression of the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) contribute to hypoxia-induced pulmonary hypertension (PH). To examine the role of Nox4 activity in pulmonary vascular cell proliferation and PH, the current study used a novel Nox4 inhibitor, GKT137831, in hypoxia-exposed human pulmonary artery endothelial or smooth muscle cells (HPAECs or HPASMCs) in vitro and in hypoxia-treated mice in vivo. HPAECs or HPASMCs were exposed to normoxia or hypoxia (1% O(2)) for 72 hours with or without GKT137831. Cell proliferation and Nox4, PPARγ, and transforming growth factor (TGF)β1 expression were measured. C57Bl/6 mice were exposed to normoxia or hypoxia (10% O(2)) for 3 weeks with or without GKT137831 treatment during the final 10 days of exposure. Lung PPARγ and TGF-β1 expression, right ventricular hypertrophy (RVH), right ventricular systolic pressure (RVSP), and pulmonary vascular remodeling were measured. GKT137831 attenuated hypoxia-induced H(2)O(2) release, proliferation, and TGF-β1 expression and blunted reductions in PPARγ in HPAECs and HPASMCs in vitro. In vivo GKT137831 inhibited hypoxia-induced increases in TGF-β1 and reductions in PPARγ expression and attenuated RVH and pulmonary artery wall thickness but not increases in RVSP or muscularization of small arterioles. This study shows that Nox4 plays a critical role in modulating proliferative responses of pulmonary vascular wall cells. Targeting Nox4 with GKT137831 provides a novel strategy to attenuate hypoxia-induced alterations in pulmonary vascular wall cells that contribute to vascular remodeling and RVH, key features involved in PH pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, so far no direct antioxidative side effects of GKT 137831 were reported [392] highlighting this substance as the most promising inhibitor for Nox enzymes not only in vitro but also in vivo [94,409,411,412,413,414].”
From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [413]
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989 · cited 6×
“NADPH oxidases catalyze the reduction of molecular oxygen to generate superoxide (O2 ), hydrogen peroxide (H2O2), or secondary oxidants (7).”
BackgroundInfluentialHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Nihon-Kokyuki-Gakkai (2011) · Cited by 1,301
Vascular NAD(P)H oxidases: specific features, expression, and regulation
Lassègue, B., & Clempus, R. E. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00758.2002 · Cited by 1,032 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundGriendling, K. K., Sorescu, D., Lassègue, B., & Ushio-Fukai, M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2175 · Cited by 955 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundSuperoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847 · cited 5×
“As the predominant Nox isoform expressed in VSMCs and ECs, Nox4 constitutes an attractive target for PH therapy.”
BackgroundInfluentialNox proteins in signal transduction
Brown, D. I., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 832 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundCucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundApocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100214 · Cited by 735 · cited 1×
“Apocynin also functions as an antioxidant in vascular ECs and SMCs, cells that lack the myeloperoxidase activity necessary for apocynin activation (37).”
BackgroundStolk, J., Hiltermann, T. J., Dijkman, J. H., & Verhoeven, A. J. (1994) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.11.1.8018341 · Cited by 648
NADPH Oxidases in Cardiovascular Health and Disease
Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S., & Shah, A. M. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.691 · Cited by 630 · cited 1×
“Among these factors, NADP reduced (NADPH) oxidase enzymes that produce reactive oxygen species (ROS) contribute to the development of a variety of vascular diseases, such as atherosclerosis (4) and systemic (5) and pulmonary hypertension (6).”
BackgroundNADPH Oxidases: Functions and Pathologies in the Vasculature
Lassègue, B., & Griendling, K. K. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.181610 · Cited by 592 · cited 2×
“Nox4 was the most abundant gp91 homolog identified in endothelial cells (ECs) and VSMCs (4, 7), and its expression was associated with pulmonary vascular remodeling (10), vasoconstriction (11), and enhanced proliferation of vascular wall cells (8).”
BackgroundO'Donnell, V. B., Tew, D. G., Jones, O. T. G., & England, P. J. (1993) · Biochemical Journal · doi:10.1042/bj2900041 · Cited by 589 · cited 1×
“However, diphenyleneiodonium nonspecifically inhibits the action of multiple flavoprotein dehydrogenases (35).”
BackgroundDistinct Subcellular Localizations of Nox1 and Nox4 in Vascular Smooth Muscle Cells
Hilenski, L. L., Clempus, R. E., Quinn, M. T., Lambeth, J. D., & Griendling, K. K. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000112024.13727.2c · Cited by 573 · cited 1×
“For example, although both Nox1 and Nox4 are expressed in vascular smooth muscle cells (VSMCs), they are targeted to discreet intracellular locations, are differentially regulated in response to growth factors and vascular injury, and are activated by distinct mechanisms (9).”
BackgroundArcher, S. L., Weir, E. K., & Wilkins, M. R. (2010) · Circulation · doi:10.1161/circulationaha.108.847707 · Cited by 485 · cited 2×
“Selected HPAECs and HPASMCs were transfected with control (2) or Nox4 (1) siRNA and propogated for 96 hours.”
BackgroundMethodOxidative stress and redox signalling in cardiac hypertrophy and heart failure
Seddon, M., Looi, Y. H., & Shah, A. M. (2007) · Heart · doi:10.1136/hrt.2005.068270 · Cited by 479
Byrne, *., Grieve, D. J., Bendall, J. K., Li, J.-M., Gove, C., Lambeth, J. D., Cave, A. C., & Shah, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000099504.30207.f5 · Cited by 411 · cited 1×
“For example, Nox4 was an important mediator of cardiac hypertrophy induced by aortic constriction in an experimental pressure overload model (49).”
BackgroundSturrock, A., Cahill, B., Norman, K., Huecksteadt, T. P., Hill, K., Sanders, K., Karwande, S. V., Stringham, J. C., Bull, D. A., Gleich, M., et al. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00269.2005 · Cited by 402 · cited 1×
“On the other hand, TGF-b1 is an upstream mediator that stimulates Nox4 expression and promotes HPASMC proliferation in normoxic (29) and hypoxic (24) environments.”
BackgroundMasri, F. A., Xu, W., Comhair, S. A. A., Asosingh, K., Koo, M., Vasanji, A., Drazba, J., Anand-Apte, B., & Erzurum, S. C. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00428.2006 · Cited by 376 · cited 2×
“To further confirm the relevance of hypoxia-induced increases in Nox4 expression and decreases in PPARg expression, the expression of these targets was examined in lysates of pulmonary artery endothelial cells isolated from control subjects or patients with IPAH as previously described (23).”
BackgroundHansmann, G., de Jesus Perez, V. A., Alastalo, T.-P., Alvira, C. M., Guignabert, C., Bekker, J. M., Schellong, S., Urashima, T., Wang, L., Morrell, N. W., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32503 · Cited by 367 · cited 1×
“Targeted deletion of PPARg in endothelial (44) or smooth muscle cells (45) is associated with the spontaneous development of PH.”
BackgroundHansmann, G., Wagner, R. A., Schellong, S., de Jesus Perez, V. A., Urashima, T., Wang, L., Sheikh, A. Y., Suen, R. S., Stewart, D. J., & Rabinovitch, M. (2007) · Circulation · doi:10.1161/circulationaha.106.663120 · Cited by 366
Aoyama, T., Paik, Y.-H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., et al. (2012) · Hepatology · doi:10.1002/hep.25938 · Cited by 336
Self-citationMittal, M., Roth, M., König, P., Hofmann, S., Dony, E., Goyal, P., Selbitz, A.-C., Schermuly, R. T., Ghofrani, H. A., Kwapiszewska, G., et al. (2007) · Circulation Research · doi:10.1161/circresaha.107.148015 · Cited by 326 · cited 13×
“Nox4 was selectively up-regulated in the pulmonary arteries of chronic hypoxia-exposed mice and in the vascular lesions of patients with idiopathic pulmonary arterial hypertension (IPAH) (10).”
BackgroundMethodInfluentialBurgess, H. A., Daugherty, L. E., Thatcher, T. H., Lakatos, H. F., Ray, D. M., Redonnet, M., Phipps, R. P., & Sime, P. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00383.2004 · Cited by 317
The NADPH Oxidase Subunit NOX4 Is a New Target Gene of the Hypoxia-inducible Factor-1
Diebold, I., Petry, A., Hess, J., & Görlach, A. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-12-1003 · Cited by 296 · cited 1×
“Hypoxia is a potent proliferative stimulus that can enhance PASMC proliferation in a Nox4-mediated manner (13, 24, 25).”
BackgroundAmeshima, S., Golpon, H., Cool, C. D., Chan, D., Vandivier, R. W., Gardai, S. J., Wick, M., Nemenoff, R. A., Geraci, M. W., & Voelkel, N. F. (2003) · Circulation Research · doi:10.1161/01.res.0000073585.50092.14 · Cited by 292 · cited 2×
“PPARg, an important regulator of lipid and glucose metabolism (14), modulates growth and proliferation of ECs (15) and SMCs (16).”
BackgroundHypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox)
Liu, J. Q., Zelko, I. N., Erbynn, E. M., Sham, J. S. K., & Folz, R. J. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00135.2005 · Cited by 275 · cited 1×
“Among these factors, NADP reduced (NADPH) oxidase enzymes that produce reactive oxygen species (ROS) contribute to the development of a variety of vascular diseases, such as atherosclerosis (4) and systemic (5) and pulmonary hypertension (6).”
BackgroundTENFREYHAUS, H., HUNTGEBURTH, M., WINGLER, K., SCHNITKER, J., BAUMER, A., VANTLER, M., BEKHITE, M., WARTENBERG, M., SAUER, H., & ROSENKRANZ, S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.022 · Cited by 259
Jiang, J. X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schröder, K., Brandes, R. P., Devaraj, S., & Török, N. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.007 · Cited by 251 · cited 1×
“GKT137831 had no radical scavenging or antioxidant activity and did not show significant in vitro offtarget inhibition of 170 different proteins, indicating high Nox specificity (21, 22).”
BackgroundSelf-citationLaleu, B., Gaggini, F., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S., Gradia, A., Duboux, G., Merlot, C., Heitz, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100773e · Cited by 243 · cited 1×
“Recently, pyrazolopyridine derivatives have been reported to inhibit NADPH oxidases with a high potency and specific affinity for Nox1 and Nox4 isoforms (38, 39).”
BackgroundSelf-citationSmall-Molecule NOX Inhibitors: ROS-Generating NADPH Oxidases as Therapeutic Targets
Jaquet, V., Scapozza, L., Clark, R. A., Krause, K.-H., & Lambeth, J. D. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2585 · Cited by 243
Rosiglitazone Attenuates Chronic Hypoxia–Induced Pulmonary Hypertension in a Mouse Model
Nisbet, R. E., Bland, J. M., Kleinhenz, D. J., Mitchell, P. O., Walp, E. R., Sutliff, R. L., & Hart, C. M. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0132oc · Cited by 188 · cited 10×
“Chronic hypoxia– induced increases in Nox4 were also associated with reductions in the expression of the nuclear transcription factor, peroxisome proliferator-activated receptor g (PPARg), in HPASMCs and human pulmonary artery endothelial cells (HPAECs) (12).”
BackgroundMethodSelf-citationIsmail, S., Sturrock, A., Wu, P., Cahill, B., Norman, K., Huecksteadt, T., Sanders, K., Kennedy, T., & Hoidal, J. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90488.2008 · Cited by 177 · cited 3×
“On the other hand, TGF-b1 is an upstream mediator that stimulates Nox4 expression and promotes HPASMC proliferation in normoxic (29) and hypoxic (24) environments.”
BackgroundMethodGuignabert, C., Alvira, C. M., Alastalo, T., Sawada, H., Hansmann, G., Zhao, M., Wang, L., El‐Bizri, N., & Rabinovitch, M. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00199.2009 · Cited by 158 · cited 1×
“Targeted deletion of PPARg in endothelial (44) or smooth muscle cells (45) is associated with the spontaneous development of PH.”
BackgroundRosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling
Crossno, J. T., Garat, C. V., Reusch, J. E. B., Morris, K. G., Dempsey, E. C., McMurtry, I. F., Stenmark, K. R., & Klemm, D. J. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00258.2006 · Cited by 158 · cited 3×
“First, previous studies in a rat model of hypoxia-induced PH described a similar scenario wherein a therapeutic intervention attenuated hypoxia-induced increases in RVH without lowering RVSP due to persistent rho kinase-mediated pulmonary arterial vasoconstriction (18).”
BackgroundFresquet, F., Pourageaud, F., Leblais, V., Brandes, R. P., Savineau, J., Marthan, R., & Muller, B. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706779 · Cited by 142 · cited 2×
“Hypoxia exposure increases H2O2 generation by pulmonary vascular wall cells (3, 13), and hypoxia-induced increases in HPASMC H2O2 release and proliferation are abrogated by Nox4 siRNA (13).”
BackgroundLu, X., Murphy, T. C., Nanes, M. S., & Hart, C. M. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00090.2010 · Cited by 136 · cited 9×
“GKT137831 was used in the current study for its ability to specifically inhibit the Nox4 isoform, which has been shown to be selectively up-regulated in hypoxia (10) and associated with hypoxia-induced HPASMC proliferation (13, 24), vascular remodeling, and PH (10, 12).”
BackgroundMethodSelf-citationSturrock, A., Huecksteadt, T. P., Norman, K., Sanders, K., Murphy, T. M., Chitano, P., Wilson, K., Hoidal, J. R., & Kennedy, T. P. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00430.2006 · Cited by 132
Self-citationFukunaga, Y., Itoh, H., Doi, K., Tanaka, T., Yamashita, J. K., Chun, T., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00430-0 · Cited by 101 · cited 1×
“PPARg, an important regulator of lipid and glucose metabolism (14), modulates growth and proliferation of ECs (15) and SMCs (16).”
Backgroundde Dios, S. T., Bruemmer, D., Dilley, R. J., Ivey, M. E., Jennings, G. L. R., Law, R. E., & Little, P. J. (2003) · Circulation · doi:10.1161/01.cir.0000074040.31731.96 · Cited by 87 · cited 1×
“PPARg, an important regulator of lipid and glucose metabolism (14), modulates growth and proliferation of ECs (15) and SMCs (16).”
BackgroundRosiglitazone attenuates hypoxia‐induced pulmonary arterial hypertension in rats
Kim, E. K., Lee, J., Oh, Y., Lee, Y., & Lee, S. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01756.x · Cited by 83 · cited 3×
“reduces PPARg expression in the lung (17) and in vascular wall”
BackgroundOxidative stress modulates PPARγ in vascular endothelial cells
Blanquicett, C., Kang, B.-Y., Ritzenthaler, J. D., Jones, D. P., & Hart, C. M. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.007 · Cited by 82 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundSelf-citationNADPH oxidase inhibitors: a patent review
Kim, J.-A., Neupane, G. P., Lee, E. S., Jeong, B.-S., Park, B. C., & Thapa, P. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.584870 · Cited by 69 · cited 1×
“Recently, pyrazolopyridine derivatives have been reported to inhibit NADPH oxidases with a high potency and specific affinity for Nox1 and Nox4 isoforms (38, 39).”
BackgroundGong, K., Xing, D., Li, P., Aksut, B., Ambalavanan, N., Yang, Q., Nozell, S. E., Oparil, S., & Chen, Y.-F. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00062.2011 · Cited by 61
Matsuda, Y., Hoshikawa, Y., Ameshima, S., Suzuki, S., Okada, Y., Tabata, T., Sugawara, T., Matsumura, Y., & Kondo, T. (2005) · PubMed · Cited by 61
Meredith, D., Panchatcharam, M., Miriyala, S., Tsai, Y.-S., Morris, A. J., Maeda, N., Stouffer, G. A., & Smyth, S. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.184234 · Cited by 55 · cited 1×
“Loss of PPARg is associated with SMC proliferation, migration, and vascular remodeling (43).”
BackgroundSmall-Molecule Inhibitors of NADPH Oxidase 4
Borbély, G., Szabadkai, I., Horváth, Z., Markó, P., Varga, Z., Breza, N., Baska, F., Vántus, T., Huszár, M., Geiszt, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004368 · Cited by 53
Roles for Nox4 in the contractile response of bovine pulmonary arteries to hypoxia
Ahmad, M., Kelly, M. R., Zhao, X., Kandhi, S., & Wolin, M. S. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01228.2009 · Cited by 53 · cited 1×
“Nox4 was the most abundant gp91 homolog identified in endothelial cells (ECs) and VSMCs (4, 7), and its expression was associated with pulmonary vascular remodeling (10), vasoconstriction (11), and enhanced proliferation of vascular wall cells (8).”
BackgroundNicola, T., Ambalavanan, N., Zhang, W., James, M. L., Rehan, V. K., Halloran, B., Olave, N. C., Bulger, A., Oparil, S., & Chen, Y.-F. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00074.2011 · Cited by 50
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Functions of ROS in Macrophages and Antimicrobial Immunity
Herb, M., & Schramm, M. (2021) · Antioxidants · doi:10.3390/antiox10020313 · Cited by 633
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
“Another role for NOX4 in pulmonary vessels was suggested, as GKT137831 treatment prevented hypoxia-induced right ventricle hypertrophy, thereby attenuating pulmonary hypertension (65).”
BackgroundNADPH Oxidases in Vascular Pathology
Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., & Guzik, T. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5607 · Cited by 452
Pulmonary Arterial Hypertension: The Clinical Syndrome
Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014) · Circulation Research · doi:10.1161/circresaha.115.301146 · Cited by 402
“RNA–mediated knockdown of Nox4 or Nox4 inhibitor GKT137831 attenuated vascular remodeling.(104,105) A cross-”
Background
Metadata
- Authors
- Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M.
- Affiliations
- Emory University (US)
- Genkyotex (Switzerland) (CH)
- Corresponding author
- Hart, C. Michael
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-01
- Volume
- 47
- Issue
- 5
- Pages
- 718-726
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC3547100
- OpenAlex
- W1990038383
- Cited by
- 146
- References
- 50
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 14 · 2018: 18 · 2017: 19 · 2016: 16 · 2015: 11 · 2014: 14 · 2013: 13
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (NHLBI T32, HL081064, HL 60917)
- National Heart, Lung, and Blood Institute (HL-60917, HL-081064, T32HL076118, P01HL081064, R01HL102167, R01HL060917)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074518)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- NOX4, GKT137831, NADPH oxidase inhibitors, hypoxia, pulmonary hypertension, PPARγ, TGF-β1, pulmonary artery endothelial cells, pulmonary artery smooth muscle cells, right ventricular hypertrophy, pulmonary vascular remodeling, hydrogen peroxide
- MeSH terms
- NADPH Oxidase 4, Rosiglitazone, Animals, Cells, Cultured, Endothelium, Vascular, Humans, Hydrogen Peroxide, Hypertension, Pulmonary, Lung, Mice, Inbred C57BL, Pulmonary Artery, Pyrazoles, Pyridines, Pyridones, Cell Hypoxia, Gene Expression, Proliferating Cell Nuclear Antigen, NADPH Oxidases, Ventricular Remodeling, Myocytes, Smooth Muscle, RNA Interference, Endothelial Cells, Thiazolidinediones, Pyrazolones, PPAR gamma, Cell Proliferation, Mice, Transforming Growth Factor beta1, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.